Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Resources>Posters>This Poster
  Posters



Random Homozygous Gene Perturbation (RHGP) as a Tool for Target Discovery and Validation


Random homozygous gene perturbation (RHGP) can identify and validate any host (cellular) gene target that directly causes a desired phenotype without requiring prior knowledge of the target. The central feature of RHGP is a unique lentiviral-based genetic element, known as a gene search vector (GSV) designed to interrogate the entire genome and identify target genes that cause the phenotype of interest.

Date Posted: 24/09/2012

Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
NIH Launches Largest Clinical Trial Focused on HIV-related Cardiovascular Disease
Clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events.
No Evidence to Change Current Transfusion Practices for Adults
Study found no difference in the primary clinical measure between complex cardiac surgery patients.
Personalized Melanoma Vaccines Marshal Powerful Immune Response
Vaccines target unique mutations in each patient’s tumor.
Repurposed Experimental Cancer Drug Restores Brain Function in Mouse Models
NIH-supported research enables clinical trial to explore treatment for most common form of dementia.
Experimental Ebola Vaccine Safe, Prompts Immune Response
Results from US government-sponsored phase 1 trial of VSV vaccine reported.
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
NIH Works to Improve Kidney Health for All
Statement of NIDDK Director Griffin P. Rodgers, M.D., for World Kidney Day 2015.
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study
Phase 1 study to evaluate the novel oncology immunotherapeutic MOR209/ES414 for prostate cancer.
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters